Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Epilepsy
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Epilepsy
    TopAbstracts in Epilepsy 10/29/2009 - (DGNews)
    Eslicarbazepine Acetate Improves Quality of Life in Patients With Epilepsy: Presented at ANA - (DGDispatch)
    TopAbstracts in Epilepsy 10/15/2009 - (DGNews)
    Adjuvant Therapy Eslicarbazepine Acetate Reduces Seizure Frequency in Epileptic Patients: Presented at ANA - (DGDispatch)
    Lacosamide Decreases Seizure Frequency in Epileptic Patients: Presented at ANA - (DGDispatch)

    News archive

     Recent webcasts/CME - Epilepsy
    • Improving Epilepsy Management Throughout the Disease Continuum
    • Generalized Convulsive Status Epilepticus Guillain Barre Syndrome
      Understanding the Ramifications of Switching Among AED's: A 2008 Clinical Update

      Webcasts/CME archive

       Recent cases - Epilepsy
        Acute Pancreatitis Associated to the Use of Valproic Acid
        Diarrhea, Negative T-Waves, Fever and Skin Rash, Rare Manifestation of Carbamazepine Hypersensitivity: A Case Report
        Syncope Due to Asystole During Epilepsy. A Case Report
        Lennox Gastaut Syndrome, Review of the Literature and a Case Report
        Partial Trisomy 13q22-qter Associated to Leukoencephalopathy and Late Onset Generalised Epilepsy

        Cases archive
          




        my personal edition > epilepsy > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Low-Dose Oxcarbazepine Well Tolerated In Infants, Adolescents With Partial Seizures: Presented at AES

        By Bonnie Darves

        NEW ORLEANS, LA -- December 9, 2004 -- The relatively new antiepileptic drug oxcarbazepine as monotherapy may provide safe seizure control in infants and young children with poorly controlled or new-onset seizures, even a low doses.

        The findings were presented here on December 7th at the American Epilespy Meeting Annual Meeting.

        The multicentre randomized study enrolled 92 patients aged 1 month to 17 years, said study co-author Ricardo Ayala, neurologist, Tallahassee Neurological Clinic, Tallahassee, Florida, United States.

        Results show that there was no statistically significant difference in efficacy rates between the 10 mg/kg.day and 60 mg/kg/day, and exit rates for the the two groups were similar, the researcher said.

        Perhaps because of the study's short duration -- conducted over 5 days, with continuous video electroencephalographic (EEG) monitoring, there was no difference in mean rates of partial-seizures between the low-dose and high-dose groups, and the drug was well tolerated, Dr. Ayala said. Mean daily seizure frequency was 1.0 in the low dose group and 1.3 in the high-dose group.

        Study subjects were on at least one concomitant antiepileptic at randomisation and had discontinued all other antiepileptic therapy a week prior to pre-randomisation. They were hospitalised for the 5-day period for initiation of, or conversion to oxcarbazepine monotherapy.

        Six patients (7%) discontinued the study treatment prematurely because of either adverse events or administrative problems. Common adverse events were dizziness, somnolence, nausea and vomiting, but all adverse events occurred only in the high-dose group and affected 10% of these patients. There were no unexpected findings on electroencephalographic EEG or vital sign measurements, Dr. Ayala added.

        He noted that the low dose, 10 mg/kg daily, is equivalent to the adult dose of 600 mg/kg daily, which has been shown to reduce seizure frequency significantly in adults.

        The study was supported by Novartis.


        [Presentation title: "A Multi-Center, Rater-Blind, Randomized, Age-Stratified, Parallel-Group Study Comparing High- Vs. Low-Dose Oxcarbazepine Monotherapy in Pediatric Patients With Inadequately-Controlled Partial Seizures." Abstract 2.375]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send